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Inadvertent Iodine E:xcess Causing 
Thyroto:xic Hypokalemic Periodic Paralysis 
T he recent interesting article by Ohye et al 1 
addressed the continuing problem of nonpre-
scribed and occult medication use. l applaud 
the scientific dedication of the 2 lead authors who 
took it upon themselves to ingest the implicated tab-
lets, which have been analyzed to contain portions of 
tetraiodothyronine (T 4) and triiodothyronine (T 3).
Most would have been convinced without the need to 
take this extra step, which is unnecessary for 2 rea-
sons. The first is that data on the pharmacokinetic of 
T3 and T4 are well established. 2 The 34 µg to 45 µg of 
T4 would have few biological effects owing to the 
binding of T4 to circulating proteins. As the half-life of 
T4 is 7 to 10 days, a good 4 to 6 weeks of consistent T4
ingestion would need to occur to ensure a therapeutic 
level. The elevated T3 level is consistent with its short 
half-life,  and the dose approximates that used 
therapeutically. Thus, its transient use is reflected 
biologically in a mild reduction in thyroid-stimulating 
hormone level. The second reason is the effect of self-
testing, which may unmask other unheralded medical 
conditions, particularly that which is specific to my 
and the authors' heritage. This is best highlighted in 
the following clinical vignette. 
A 35-year-old male triathlete of Asian descent was 
seen for recurrent weakness in both lower limbs, par-
ticularly at night and after exercise. He was previously 
generally healthy with no thyroid disease. Findings 
from clinical examination showed a thin, fit-looking 
man who weighed 58 kg and was 1.68 m tall (body 
mass index [calculated as weight in kilograms divided 
by the square of height in meters), approximately 20). 
His resting pulse rate was 92 beats/min with a mild 
peripheral tremor and brisk reflexes but no goiter. His 
potassium level was 1.8 mmol/L; thyrotropin, 0.05 
mIU/L; free T4 , 2.4 ng/dL (30. 7 pmol/L) (reference 
range, 0.8-1.9 ng/dL [10.0-24.5 pmol/L]); and free T3 , 
577.9 pg/dL (8.9 pmol/L) (reference range, 246.8-
441.6 pg/dL [3.8-6.8 pmol/L]). His serum thyroglobu-
lin level was 109.5 ng/mL (reference range, < 3 2  
ng/mL), and his thyroid pertechnetate uptake scan 
was markedly reduced. On further questioning, he 
admitted to taking 5, sometimes up to IO, kelp tablets 
daily in the belief that they would improve his general 
strength and endurance. According to the product 
information, each tablet contains approximately 50 µg 
of iodine. His urinary iodine excretion was consistent 
with iodine overload at 155 µg/L (urinary iodine reple-
tion status, > 100 µg/L). His periodic weakness disap-
peared after he was advised to cease self-administering 
the tablets. At 6-month follow-up, he was euthyroid 
both clinically and biochemically with a serum potas-
sium level of 4.1 mEq/L. 
This voluntary T 4 and T 3 challenge test is not new and 
historically was well described by Shinosaki in 1925. 3 
Large doses of thyroid extract were experimentally given 
to 7 patients ( with controls) with a clinical history of pe-
riodic paralysis. The result was a definite increase in the 
frequency and severity of the paralytic attacks. 
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In reply 
The vignette by Tran regarding his patient is irrelevant to 
our study. Tran's intriguing case requires further study 
before reporting. Can he reproduce the same clinical pic-
ture by giving iodine or kelp to his patient? Does his 
patient have any underlying thyroid disease? Did he mea-
sure thyroid hormone content in the kelp preparation? 
Many questions can be raised before accepting his con-
cept of  kelp-induced hypokalemia periodic paralysis in 
thyrotoxicosis. Administration of herb medicines to the 2 
authors can be easily justified because T3 and T4 contents 
in the herb medicines were not known at that time. 
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Antlretrovlral Therapy and the Prevalence 
and Incidence of  Diabetes 
I n the study by Brown et al, 1 the authors did not men-tion several limitations that might have an impor-tant impact on the interpretation of the results. First, 
the study only included men, who were mostly white (ap-
proximately 86%). Therefore, the results cannot be ex-
trapolated to women and other ethnic groups. Second, 
the family history of diabetes was not ascertained in the 
study participants, and this could have confounded the 
magnitude of differences in prevalence and incidence of 
diabetes between the 2 study groups. Third, the re-
ported prevalence and incidence rates of diabetes were 
likely to be overestimated because the diagnosis of dia-
betes was not confirmed by a repeated measurement of 
fasting plasma glucose. 
In addition, the article 1 suffered from multiple 
errors in the organization of the references that led to 
significant confusion and sometimes difficulty in fol-
lowing the manuscript. In fact, several references men-
tioned in the text did not match the references listed 
at the end of the article. Thus, reference numbers 5, 6, 
7, 8, 9, 11, 12, 15, and 26 in the text were misplaced 
and corresponded to reference numbers 7, 8, 9, 1, 10, 
12, 11, 16, and 27, respectively, in the list of refer-
ences. 1 
Finally, the publication year of the study by Walli et 
al, 2 reference number 7 in the list of references, 1 is 1998 
and not 2001. 
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In reply 
Mikhail and Cope comment on our recent article, "Anti-
retroviral Therapy and the Prevalence and Incidence of 
Diabetes Mellitus in the Multicenter AIDS Cohort 
Study,"1 in which we conclude that the incidence of diabe-
tes mellitus in men with human immunodeficiency virus 
(HIV) infection undergoing highly active antiretroviral 
therapy (HAART) was 4 times greater than that found in 
HIV-seronegative men. 
First, Mikhail and Cope state that we did not mention 
that our results cannot be extrapolated to women or non-
white racial groups. Our results may or may not general-
ize to women and nonwhite racial groups as stated in the 
second paragraph of the "Comment" section. Indeed, the 
rate ratio of diabetes mellitus owing to HIV and HAART 
will generalize to these other groups if  sex and race do 
not modify the relation between HIV and HAART and 
diabetes mellitus, assuming there is no measurement 
error. Second, Mikhail and Cope correctly point out that 
we did not account for family history in the analysis pre-
sented in our article. Family history data were available 
from April 2000 onward in our cohort, a year after the 
baseline visit for our analysis. Adjusting for family his-
tory of diabetes when possible in the incidence analysis 
alters the summary rate ratio for HIV-infected men 
receiving HAART compared with men without HIV from 
4.1 (95% confidence interval, 1.85-9.16) to 3.9 (95% con-
fidence interval, 1. 75-8. 72), a 5% change. Therefore, 
accounting for measured family history does not affect 
the interpretation of our findings. Third, Mikhail and 
Cope state that we did not mention the limitation that we 
defined diabetes mellitus based on a single fasting glucose 
measurement, but this is the first limitation addressed in 
the last paragraph of the "Comment" section. 
Finally, Mikhail and Cope astutely observe that the 
references were not published in the correct sequence; the 
ARCHIVES is publishing a correction in this issue for the 
misnumbered reference section. 
Todd T. Brown, MD 
Stephen R. Cole, PhD 
Xiuhong Li, MSc 
Correspondence: Dr Brown, The Johns Hopkins Uni-
versity School of Medicine, 1830 E Monument St, No. 
333, Baltimore, MD 21287 (tbrown27@jhmi.edu). 
l .  Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and 
incidence of diabetes mellitus in the Multicenter AIDS Cohort Study. Arch 
Intern Med. 2005;165:1179-1184. 
Dif ferent ia l  Loss t o  Fol low-up b y  Insurance  
S t a t u s  in t h e  Hea l th  a n d  R e t i r e m e n t  S t u d y :  
Implicat ions f o r  N a t i o n a l  Es t imates  
o n  Hea l th  Insurance  C o v e r a g e
W e read with interest the article by Baker and Sudano 1 titled "Health Insurance Coverage During the Years Preceding Medicare Eligi-
bility." The combination oflacking health insurance and 
the benefits from affordability of medical care that come 
with health insurance are greatest in the years preceding 
Medicare eligibility. Baker and Sudano 1 estimated the per-
centage of uninsured individuals as the Health and Retire-
ment Study (HRS) cohort aged over time. They found that 
the percentage uninsured respondents aged 51 to 57 years 
in the baseline wave dropped from 14.3% in 1992 to 8.2% 
in 2000. We used the Current Population Survey's (CPS) 
Annual Demographic Survey, a nationally representative 
cross-sectional survey of 50 000 households conducted by 
the Bureau of the Census, to estimate the percentage un-
insured for the same age cohorts and found it to be stable 
between 1992 and 2000 (Table). 
Table. Percentage Uninsured From 1992 to 2000 
% Uninsured 
Year Age Cohort, y HRS* 
1992 51-57 14.3 
1994 53-59 10.8 
1996 55-61 9.7 
1998 57-63 8.8 
2000 59-64 8.2 
Abbreviations: CPS, Current Population Survey; HRS, Health and 
Retirement Study. 
*Estimates from Baker and Sudano. 1 
tEstimates from the authors' analysis of CPS. 
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